DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Other EventsItem 8.01
On December28, 2017, we entered into exchange agreements (collectively, “Exchange Agreements”), each by and between us and an investor from our June 2016 private placement of senior secured convertible notes (as further exchanged, the “Notes”) originally issued to that certain Securities Purchase Agreement, dated June6, 2016, by and among us and such investors. to the Exchange Agreements, we, among other things,issued to the investors shares (the “Shares”) of our common stock (or rights (“Rights”) to receive common stock to the extent such issuance of Shares would otherwise result in the beneficial ownership by any such investor of more than 4.9% or 9.9% of our issued and outstanding stock), as applicable, of an aggregate of 123,708,735 shares of our common stock. As of January25, 2018, all of the Rights have been exercised, and neither investor owns more than 4.9% of the issued and outstanding shares of our common stock. Since the Notes have been satisfied in full as a result of the Exchange Agreements, there is no longer a security interest in our assets with respect to the Notes. As of January 25, 2018, we had 222,981,824 shares of our common stock issued and outstanding.
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
